静脉-静脉体外膜氧合期间动脉二氧化碳轨迹与系列脑生物标志物及中枢神经系统损伤的关系:一项前瞻性队列研究
这项前瞻性队列研究纳入59例因急性呼吸衰竭接受VV-ECMO的成人患者,在启动前及启动后24小时内每2-4小时监测动脉血气,7天内检测脑生物标志物(NF-L、GFAP、磷酸化tau 181),疑有神经损伤或无法检查者在7-14天内行神经影像。12例(20%)经头颅CT发现明显CNS损伤。发生CNS损伤者PaCO2下降斜率更陡(-0.32%,95%CI -0.25至-0.39)vs 无CNS损伤者(-0.18%,95%CI -0.14至-0.21,交互作用P<0.001)。NF-L和GFAP在CNS损伤者中更高,但按三个PaCO2绝对变化阈值分层后,NF-L、GFAP和tau随时间变化无差异且无显著时间交互作用。作者认为数据重叠及PaCO2与脑生物标志物之间缺乏关系提示其他病理生理变量可能起作用。
要点
- 59例成人VV-ECMO患者中12例(20%)经头颅CT发现明显CNS损伤。
- CNS损伤者PaCO2下降斜率-0.32%(95%CI -0.25至-0.39),无CNS损伤者-0.18%(95%CI -0.14至-0.21),交互作用P<0.001。
- CNS损伤者NF-L均值464(739)vs 无CNS损伤者127(257),P=0.001;GFAP 4278(11,653)pg/ml vs 116(108)pg/ml,P<0.001。
- 按三个PaCO2绝对变化阈值分层,NF-L、GFAP和tau随时间变化无差异且无显著时间交互作用。
- 作者认为PaCO2与脑生物标志物缺乏关系提示其他病理生理变量可能起作用。
适用人群与场景
- 因急性呼吸衰竭接受VV-ECMO的成人患者。
研究设计与关键结果
- 前瞻性队列研究,纳入59例因急性呼吸衰竭接受VV-ECMO的成人患者。
- 12/59(20%)患者经头颅CT发现明显CNS损伤。
- VV-ECMO启动后PaCO2下降斜率:CNS损伤组-0.32%(95%CI -0.25至-0.39)vs 无CNS损伤组-0.18%(95%CI -0.14至-0.21),交互作用P<0.001。
- NF-L平均浓度随时间升高,CNS损伤组464(739)vs 无CNS损伤组127(257),P=0.001。
- GFAP:CNS损伤组4278(11,653)pg/ml vs 无CNS损伤组116(108)pg/ml,P<0.001。
- 按三个PaCO2绝对变化阈值分层的NF-L、GFAP和tau随时间变化无差异,无显著时间交互作用。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管VV-ECMO启动后PaCO2快速下降在发生CNS损伤者中略大于未发生者,但数据重叠及PaCO2与脑生物标志物之间缺乏关系提示其他病理生理变量可能起作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Central nervous system (CNS) injury following initiation of veno-venous extracorporeal membrane oxygenation (VV-ECMO) is common. An acute decrease in partial pressure of arterial carbon dioxide (PaCO2) following VV-ECMO initiation has been suggested as an etiological factor, but the challenges of diagnosing CNS injuries has made discerning a relationship between PaCO2 and CNS injury difficult.
METHODS: We conducted a prospective cohort study of adult patients undergoing VV-ECMO for acute respiratory failure. Arterial blood gas measurements were obtained prior to initiation of VV-ECMO, and at every 2-4 h for the first 24 h. Neuroimaging was conducted within the first 7-14 days in patients who were suspected of having neurological injury or unable to be examined because of sedation. We collected blood biospecimens to measure brain biomarkers [neurofilament light (NF-L); glial fibrillary acidic protein (GFAP); and phosphorylated-tau 181] in the first 7 days following initiation of VV-ECMO. We assessed the relationship between both PaCO2 over the first 24 h and brain biomarkers with CNS injury using mixed methods linear regression. Finally, we explored the effects of absolute change of PaCO2 on serum levels of neurological biomarkers by separate mixed methods linear regression for each biomarker using three PaCO2 exposures hypothesized to result in CNS injury.
RESULTS: In our cohort, 12 of 59 (20%) patients had overt CNS injury identified on head computed tomography. The PaCO2 decrease with VV-ECMO initiation was steeper in patients who developed a CNS injury (- 0.32%, 95% confidence interval - 0.25 to - 0.39) compared with those without (- 0.18%, 95% confidence interval - 0.14 to - 0.21, P interaction < 0.001). The mean concentration of NF-L increased over time and was higher in those with a CNS injury (464 [739]) compared with those without (127 [257]; P = 0.001). GFAP was higher in those with a CNS injury (4278 [11,653] pg/ml) compared with those without (116 [108] pg/ml; P < 0.001). The mean NF-L, GFAP, and tau over time in patients stratified by the three thresholds of absolute change of PaCO2 showed no differences and had no significant interaction for time.
CONCLUSIONS: Although rapid decreases in PaCO2 following initiation of VV-ECMO were slightly greater in patients who had CNS injuries versus those without, data overlap and absence of relationships between PaCO2 and brain biomarkers suggests other pathophysiologic variables are likely at play.
参考来源
- Thiara S, Stukas S, Hoiland R, et al. Characterizing the Relationship Between Arterial Carbon Dioxide Trajectory and Serial Brain Biomarkers with Central Nervous System Injury During Veno-Venous Extracorporeal Membrane Oxygenation: A Prospective Cohort Study. Neurocrit Care. 2024. PMID: 38302643. doi:10.1007/s12028-023-01923-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。